Brian Helfand, MD, PhD, describes the ways in which the PSA nadir can be defined after definitive therapy and the implications of the definition used for patients with prostate cancer.
Judd W. Moul, MD, FACS
Advertisement
Articles by Judd W. Moul, MD, FACS
Experts from the Duke Cancer Institute outline their current approach to stratifying surgical management of patients with prostate cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Revolutionizing Oncology in the Digital Age: Effects on Health Care Providers
2
How Do You Choose The Right Frontline Therapy in CLL Care?
3
3 Things You Should Know About Using Selective Estrogen Receptor Degraders in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
4
From Conference to Practice: Top 5 Takeaways From EHA 2026
5